CLAIMS

1. Use of 2-{3-[4-(1H-indazol-5-ylamino)-2-quinazolinyl]phenoxy}-N-(propan-2-yl) acetamide, or a pharmaceutically acceptable salt thereof, for the preparation of a pharmaceutical composition, medicament, or product for treating a patient who experiences one or more treatment-related, adverse reactions while receiving a clinically-recommended dose of the 2-{3-[4-(1H-indazol-5-ylamino)-2-quinazolinyl]phenoxy}-N-(propan-2-yl) acetamide, or the pharmaceutically acceptable salt thereof, comprising:

   administration of the 2-{3-[4-(1H-indazol-5-ylamino)-2-quinazolinyl]phenoxy}-N-(propan-2-yl) acetamide, or the pharmaceutically acceptable salt thereof is to be ceased to the patient if the patient experiences at least one adverse reaction at a Grade 3 level or higher; and

   administration of the 2-{3-[4-(1H-indazol-5-ylamino)-2-quinazolinyl]phenoxy}-N-(propan-2-yl) acetamide, or the pharmaceutically acceptable salt thereof is to be resumed at a clinically recommended dose for the patient if the at least one adverse reaction did not rise to a Grade 4 level and the patient recovered to a Grade 1 level or less after the administration of 2-{3-[4-(1H-indazol-5-ylamino)-2-quinazolinyl]phenoxy}-N-(propan-2-yl) acetamide, or the pharmaceutically acceptable salt thereof was ceased.

2. The use according to claim 1, comprising the steps of:
   (a) the 2-{3-[4-(1H-indazol-5-ylamino)-2-quinazolinyl]phenoxy}-N-(propan-2-yl) acetamide, or the pharmaceutically acceptable salt thereof is to be administered to the patient at the clinically recommended dose for the patient;
   (b) the patient is to be monitored for adverse reactions;
   (c) administration of the 2-{3-[4-(1H-indazol-5-ylamino)-2-quinazolinyl]phenoxy}-N-(propan-2-yl) acetamide, or the pharmaceutically acceptable salt thereof is to be ceased to the patient if the patient experiences at least one adverse reaction at a Grade 3 level; and
   (d) administration of the 2-{3-[4-(1H-indazol-5-ylamino)-2-quinazolinyl]phenoxy}-N-(propan-2-yl) acetamide, or the pharmaceutically

acceptable salt thereof is to be resumed to the patient when the patient's at least one adverse reaction has recovered to Grade 1 or less.

3. The use according to claim 1 or claim 2, wherein the at least one adverse reaction of the patient has recovered to Grade 0 after cessation of the 2-{3-[4-(1H-indazol-5-ylamino)-2-quinazolinyl]phenoxy}-N-(propan-2-yl) acetamide, or the pharmaceutically acceptable salt thereof administration.

4. The use according to claim 1, comprises the administration of the 2-{3-[4-(1H-indazol-5-ylamino)-2-quinazolinyl]phenoxy}-N-(propan-2-yl) acetamide, or the pharmaceutically acceptable salt thereof is to be permanently ceased to the patient if the patient experiences at least one adverse reaction at a Grade 4 level.

5. The use according to claim 3, wherein the patient is to be monitored for adverse reactions at least monthly.

6. The use according to claim 1 or 2, wherein the 2-{3-[4-(1H-indazol-5-ylamino)-2-quinazolinyl]phenoxy}-N-(propan-2-yl) acetamide, or the pharmaceutically acceptable salt thereof, is 2-{3-[4-(1H-indazol-5-ylamino)-2-quinazolinyl]phenoxy}-N-(propan-2-yl) acetamide mesylate salt.

7. The use according to claim 1 or 2, wherein the clinically recommended dose for the patient is a dose equivalent to 200 mg of the free base a day prior to and after the patient experiences at least one treatment-related, adverse reaction.

8. The use according to claim 1 or 2, wherein the clinically recommended dose for the patient is a dose equivalent to 200 mg of the free base taken once daily with food.

9. The use according to claim 1 or 2, wherein the clinically recommended dose for the patient is a dose equivalent to 400 mg of the free base a day prior to and after the patient experiences at least one treatment-related adverse reaction.

10. The use according to claim 1 or 2, wherein the clinically recommended dose for the patient is to be reduced after the patient recovers to a Grade 1 level or less and

administration of the 2-{3-[4-(1H-indazol-5-ylamino)-2-quinazolinyl]phenoxy}-N-(propan-2-yl) acetamide, or a pharmaceutically acceptable salt thereof is to be resumed.

11. The use according to claim 1 or 2, wherein the clinically recommended dose for the patient is in the range of a dose equivalent to 200 mg of the free base a day to a dose equivalent to 400 mg of the free base a day.

12. The use according to claim 1 or 2, wherein the patient has chronic graft-versus-host disease (cGVHD), optionally wherein the patient has failed at least two prior lines of systemic therapy for the cGVHD.

13. The use according to claim 1 or 2, wherein the patient's at least one adverse reaction is graded according to the Common Terminology Criteria for Adverse Events (CTCAE).

14. The use according to claim 1 or 2, wherein the at least one adverse reaction is an infection, asthenia, nausea, diarrhea, dyspnea, cough, edema, hemorrhage, abdominal pain, musculoskeletal pain, headache, phosphate decrease, gamma glutamyl transferase increase, lymphocytes decrease, or hypertension.

15. The use according to claim 1 or 2, wherein the at least one adverse reaction is:
(a) a viral infection, a bacterial infection, or an infection of unspecified pathogen, optionally wherein the infection of unspecified pathogen is acute sinusitis, device related infection, ear infection, folliculitis, gastroenteritis, gastrointestinal infection, hordeolum, infectious colitis, lung infection, skin infection, tooth infection, urinary tract infection, wound infection, upper respiratory tract infection, pneumonia, conjunctivitis, sinusitis, respiratory tract infection, bronchitis, sepsis, or septic shock; or
(b) asthenia, edema, or pyrexia; or
(c) a gastrointestinal disorder, optionally wherein the gastrointestinal disorder is nausea, diarrhea, abdominal pain, or dysphagia; or
(d) a respiratory, thoracic or mediastinal disorder, optionally wherein the respiratory, thoracic or mediastinal disorder is dyspnea, cough, or nasal congestion; or

(e) a vascular disorder, optionally wherein the vascular disorder is hemorrhage or hypertension; or

(f) a musculoskeletal or connective tissue disorder, optionally wherein the musculoskeletal or connective tissue disorder is musculoskeletal pain, muscle spasm, or arthralgia; or

(g) a nervous system disorder, optionally wherein the nervous system disorder is headache or migraine headache; or

(h) a metabolic disorder, optionally wherein the metabolic disorder is decreased appetite.